Emergent BioSolutions (LTS:0IGA) FCF Margin % : -25.10% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Emergent BioSolutions FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Emergent BioSolutions's Free Cash Flow for the three months ended in Mar. 2024 was $-73 Mil. Emergent BioSolutions's Revenue for the three months ended in Mar. 2024 was $292 Mil. Therefore, Emergent BioSolutions's FCF Margin % for the quarter that ended in Mar. 2024 was -25.10%.

As of today, Emergent BioSolutions's current FCF Yield % is -45.46%.

The historical rank and industry rank for Emergent BioSolutions's FCF Margin % or its related term are showing as below:

LTS:0IGA' s FCF Margin % Range Over the Past 10 Years
Min: -25.21 Med: 2.62 Max: 31.26
Current: -11.42

During the past 13 years, the highest FCF Margin % of Emergent BioSolutions was 31.26%. The lowest was -25.21%. And the median was 2.62%.

LTS:0IGA's FCF Margin % is ranked worse than
70.79% of 1027 companies
in the Drug Manufacturers industry
Industry Median: -0.12 vs LTS:0IGA: -11.42

Emergent BioSolutions FCF Margin % Historical Data

The historical data trend for Emergent BioSolutions's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions FCF Margin % Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

10.28

27.01

5.86

-13.93

-25.21

Emergent BioSolutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-126.17	-38.30	17.95	7.67	-25.10

Competitive Comparison of Emergent BioSolutions's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's FCF Margin % falls into.

Emergent BioSolutions FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Emergent BioSolutions's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-257.9	/	1023
	=	-25.21 %

Emergent BioSolutions's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-73.4	/	292.4
	=	-25.10 %

Emergent BioSolutions FCF Margin % Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (LTS:0IGA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (LTS:0IGA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (LTS:0IGA) Headlines

No Headlines